Background Temsirolimus has level 1 evidence for initial treatment of poor-risk patients with
advanced renal cell carcinoma (mRCC), but its efficacy has not been directly compared with …

There is a strong rationale for sequencing targeted therapy in metastatic clear cell renal
cancer. However the timing of the switch and the best agent to switch to remains unclear …

BACKGROUND This study aimed to apply the International mRCC Database Consortium
(IMDC) prognostic model in metastatic non–clear cell renal cell carcinoma (nccRCC). In …

Abstract Context The European Association of Urology Renal Cell Carcinoma Guideline
Panel recently conducted a systematic review of treatment options for patients with …

Background: About 40% of metastatic clear-cell renal cell carcinoma (m-ccRCC) patients
receive a second-line targeted therapy after failure of anti-vascular endothelial growth factor …

Multiple combinational regimens have recently been approved and are now considered the
standard of care for patients with advanced clear cell renal cell carcinoma (RCC). Several …

Introduction: Non-clear cell renal cell carcinoma (nccRCC) represents a highly
heterogenous group of kidney cancer entities. As most clinical trials predominantly include …

Oncologic treatments for renal cell carcinoma (RCC) have undergone a major revolution in
the past 2 decades, moving away from the pre-2004 Dark Age during which interleukin 2 …

Opinion statement The treatment for metastatic renal cell carcinoma (mRCC) has
significantly evolved in recent years with a deeper understanding of the molecular make-up …

Treatment options for metastatic renal cell carcinoma (RCC) continue to expand. Three
recent phase III trials, Checkmate 214, Keynote-426, and Javelin Renal 101, have led to …